Thinking of joining a study?

Register your interest

Become a volunteer?

NCT04768426 | RECRUITING | Triple Negative Breast Cancer

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Sponsor:

Stanford University

Brief Summary:

The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical trials in which patients could receive a different treatment than capecitabine to reduce their risk of breast cancer relapse.

Condition or disease

Triple Negative Breast Cancer

Breast Cancer

Intervention/treatment

Capecitabine

Phase

PHASE2

Detailed Description:

The Primary Objective is to characterize the circulating tumor DNA (ctDNA) profile of triple-negative breast cancer (TNBC) in participants with residual disease after standard neoadjuvant chemotherapy (NAC) receiving standard-of-care adjuvant capecitabine. The Secondary Objectives are to correlate ctDNA levels with genomic features and survival.

Study Type : INTERVENTIONAL
Estimated Enrollment : 40 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy
Actual Study Start Date : 2021-02-03
Estimated Primary Completion Date : 2026-02
Estimated Study Completion Date : 2026-02

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Anatomic stage I - III triple-negative breast cancer at diagnosis
  • 2. Estrogen receptors (ER) and Progesterone receptors (PR) status \<10%
  • 3. Residual disease following at least 4 cycles of neoadjuvant chemotherapy. Patients who received other investigational immunotherapy or targeted therapy during the neoadjuvant phase of treatment are eligible.
  • 4. ≥ 18 years of age
  • 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • 6. All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy.
  • 7. No evidence of metastatic disease.
  • 8. A minimum 4-week wash out from previous chemotherapy treatment is required.
  • 9. Adequate hematologic function: Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3); Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)
  • 10. Adequate hepatic function: Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN. Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN
  • 11. Adequate renal function: Serum creatinine ≤ 1.5 x ULN; or calculated creatinine clearance \> 50 mL/min using the Cockcroft Gault formula.
  • 12. Planned for 6 months or 8 cycles of adjuvant capecitabine.
  • 13. Women of childbearing potential (WOCBP) must have a negative pregnancy test.
  • 14. WOCBP must agree to use effective contraception during the study and for 3 months after the last dose.
  • 15. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.
  • 16. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria
  • 1. Metastatic breast cancer
  • 2. Has not had definitive surgical resection
  • 3. Pregnant or breastfeeding
  • 4. Has not completed definitive adjuvant radiation if planned
  • 5. Known human immunodeficiency virus (HIV) positivity or active hepatitis B or C.
  • 6. Investigational agents within 4 weeks of study initiation
  • 7. Inability to swallow oral medications
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Location Details

NCT04768426

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Stanford University

Stanford, California, United States, 94304